Menu Back toSession-0701-New-Trend-Technology-in-Biologic-Development

The 7th DIA China Annual Meeting


Session 0701 New Trend/Technology in Biologic Development

Session Chair(s)

Chengbin  Wu

Chengbin Wu

  • Chief Scientific Officer, President of R&D
  • Shanghai CP Guojian Pharmaceuticals Co. Ltd., China

Bispecific Antibody TCell Engager for Cancer Immunotherapy

Speaker(s)

Mingqiang  Zhang

Bispecific Antibody TCell Engager for Cancer Immunotherapy

Mingqiang Zhang

  • General Manager, Corporate VP of R&D
  • Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd, China
Kang  Li

Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs

Kang Li

  • Head of Biologics
  • BeiGene, China
Peter  Luo

Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs

Peter Luo

  • Co-founder and Chief Executive Officer
  • Adagene Inc., China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650